Sabra Health Care REIT, Inc.

NasdaqGS:SBRA Stock Report

Market Cap: US$4.7b

Sabra Health Care REIT Valuation

Is SBRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBRA ($19.54) is trading below our estimate of fair value ($34.44)

Significantly Below Fair Value: SBRA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBRA?

Other financial metrics that can be useful for relative valuation.

SBRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.3x
Enterprise Value/EBITDA17.3x
PEG Ratio2.6x

Price to Earnings Ratio vs Peers

How does SBRA's PE Ratio compare to its peers?

The above table shows the PE ratio for SBRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.1x
CTRE CareTrust REIT
58.3x45.5%US$5.8b
NHI National Health Investors
28.8x10.8%US$3.7b
LTC LTC Properties
17.7x-5.9%US$1.8b
OHI Omega Healthcare Investors
31.8x9.0%US$11.5b
SBRA Sabra Health Care REIT
47.6x18.3%US$4.7b

Price-To-Earnings vs Peers: SBRA is expensive based on its Price-To-Earnings Ratio (47.6x) compared to the peer average (34.1x).

Price to Earnings Ratio vs Industry

How does SBRA's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.5%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.5%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: SBRA is expensive based on its Price-To-Earnings Ratio (47.6x) compared to the Global Health Care REITs industry average (29.1x).

Price to Earnings Ratio vs Fair Ratio

What is SBRA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBRA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47.6x
Fair PE Ratio40.3x

Price-To-Earnings vs Fair Ratio: SBRA is expensive based on its Price-To-Earnings Ratio (47.6x) compared to the estimated Fair Price-To-Earnings Ratio (40.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.54
US$19.41
-0.7%
8.3%US$21.00US$16.00n/a11
Nov ’25US$18.64
US$19.05
+2.2%
7.1%US$21.00US$16.00n/a11
Oct ’25US$18.58
US$18.77
+1.0%
7.6%US$21.00US$16.00n/a11
Sep ’25US$17.04
US$17.45
+2.4%
9.3%US$21.00US$15.00n/a10
Aug ’25US$16.16
US$16.41
+1.6%
10.9%US$21.00US$14.00n/a11
Jul ’25US$15.41
US$16.18
+5.0%
10.8%US$21.00US$14.00n/a11
Jun ’25US$14.58
US$16.09
+10.4%
11.1%US$21.00US$14.00n/a11
May ’25US$13.93
US$15.91
+14.2%
12.1%US$21.00US$14.00n/a11
Apr ’25US$14.71
US$15.91
+8.2%
12.1%US$21.00US$14.00n/a11
Mar ’25US$13.99
US$15.92
+13.8%
11.6%US$21.00US$14.00n/a12
Feb ’25US$13.44
US$15.92
+18.4%
11.6%US$21.00US$14.00n/a12
Jan ’25US$14.27
US$15.27
+7.0%
4.9%US$16.00US$14.00n/a11
Dec ’24US$14.67
US$14.92
+1.7%
7.5%US$16.00US$13.00n/a12
Nov ’24US$13.92
US$14.63
+5.1%
8.5%US$16.00US$12.50US$18.6412
Oct ’24US$13.94
US$13.79
-1.1%
6.2%US$15.00US$12.50US$18.5812
Sep ’24US$12.93
US$13.21
+2.2%
7.2%US$15.00US$11.00US$17.0412
Aug ’24US$12.94
US$12.71
-1.8%
9.2%US$15.00US$11.00US$16.1612
Jul ’24US$11.77
US$12.55
+6.6%
10.4%US$15.00US$11.00US$15.4111
Jun ’24US$11.15
US$12.58
+12.9%
10.0%US$15.00US$11.00US$14.5812
May ’24US$11.36
US$12.68
+11.6%
12.2%US$15.00US$10.50US$13.9311
Apr ’24US$11.50
US$13.14
+14.2%
12.2%US$15.00US$10.50US$14.7111
Mar ’24US$11.80
US$13.71
+16.2%
8.7%US$15.00US$11.00US$13.9912
Feb ’24US$13.52
US$14.08
+4.1%
10.2%US$18.00US$12.00US$13.4413
Jan ’24US$12.43
US$14.38
+15.7%
10.4%US$18.00US$12.00US$14.2713
Dec ’23US$12.82
US$14.84
+15.8%
10.9%US$18.00US$12.00US$14.6714
Nov ’23US$13.61
US$15.45
+13.5%
12.3%US$20.00US$12.00US$13.9214

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y